<abstract xmlns="http://www.w3.org/1999/xhtml"><bold>Introduction</bold>. Skin toxicity in patients receiving novel therapeutic cancer agents has become a very important marker in determining drug activity, but it can also severely impact their quality of life. About half of the patients receiving this type of oncologic treatment will develop cutaneous reactions, that is why adequate understanding and management of these side effects is very important for drug adherence and patients’ quality of life.<bold>Materials and methods</bold>. We conducted a prospective study of consecutive patients who received oncologic treatment in our institution and presented with dermatologic side effects. The severity of skin toxicity was assessed using the DLQI score and patients were prospectively followed to evaluate response to therapy. Univariate analysis of factors influencing the impact of skin toxicity on patient QOL was conducted.<bold>Results</bold>. 52 patients were enrolled in the study. Patients who developed grade 3 and 4 skin toxicity had a higher DLQI score, with a greater impact on quality of life, but with better clinical outcome at 3 months follow-up, based on RECIST. Patients with moderate or severe cutaneous AE were more likely to achieve complete or partial response to therapy than those with mild AE (16/33 <italic>vs.</italic> 3/19, p = 0.035). Interestingly, female patients had a significantly poorer quality of life than male patients as assessed by the DLQI score (7.28 ± 7 <italic>vs</italic>. 3.7 ± 3.6, p = 0.038).<bold>Conclusion</bold>. Cutaneous side effects are often encountered in cancer patients and their severity can be a surrogate marker for a positive clinical tumor response to therapy.</abstract>

Introduction. Skin toxicity in patients receiving novel therapeutic cancer agents has become a very important marker in determining drug activity, but it can also severely impact their quality of life. About half of the patients receiving this type of oncologic treatment will develop cutaneous reactions, that is why adequate understanding and management of these side effects is very important for drug adherence and patients’ quality of life.Materials and methods. We conducted a prospective study of consecutive patients who received oncologic treatment in our institution and presented with dermatologic side effects. The severity of skin toxicity was assessed using the DLQI score and patients were prospectively followed to evaluate response to therapy. Univariate analysis of factors influencing the impact of skin toxicity on patient QOL was conducted.Results. 52 patients were enrolled in the study. Patients who developed grade 3 and 4 skin toxicity had a higher DLQI score, with a greater impact on quality of life, but with better clinical outcome at 3 months follow-up, based on RECIST. Patients with moderate or severe cutaneous AE were more likely to achieve complete or partial response to therapy than those with mild AE (16/33 vs. 3/19, p = 0.035). Interestingly, female patients had a significantly poorer quality of life than male patients as assessed by the DLQI score (7.28 ± 7 vs. 3.7 ± 3.6, p = 0.038).Conclusion. Cutaneous side effects are often encountered in cancer patients and their severity can be a surrogate marker for a positive clinical tumor response to therapy.

Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study

“UMF Carol Davila” School of Medicine

Romanian Journal of Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Introduction. Skin toxicity in patients receiving novel therapeutic cancer agents has become a very important marker in determining drug activity, but it can...

Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study

Pubblicato online: 17 mag 2018

Pagine: 96 - 101

Ricevuto: 01 gen 2018

DOI: https://doi.org/10.2478/rjim-2018-0002

Parole chiave
exanthema, toxicity, EGFR tyrosine kinase inhibitor, quality of life, chemotherapy

© 2018 Maria Alexandra Barbu et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study

Pubblicato online: 17 mag 2018

Pagine: 96 - 101

Ricevuto: 01 gen 2018

DOI: https://doi.org/10.2478/rjim-2018-0002

Parole chiaveexanthema, toxicity, EGFR tyrosine kinase inhibitor, quality of life, chemotherapy

© 2018 Maria Alexandra Barbu et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Parole chiave
exanthema, toxicity, EGFR tyrosine kinase inhibitor, quality of life, chemotherapy